Electron microscope image of cytomegalovirus Patients who experienced CMV viremia had significantly lower total protein, hemoglobin, and platelet and lymphocyte counts compared with those who did not.

Following interim results presented at the 2017 Conference on Retroviruses and Opportunistic Infections, a team of investigators from Vall d’Hebron in Spain delivered their final results at this ...

Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (SOT) Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With Cytomegalovirus (CMV) ...

− More Than Three Times as Many Transplant Recipients With Confirmed Resistant Cytomegalovirus (CMV) Infection at Baseline Receiving the Investigational Drug Maribavir Achieved CMV Viremia Clearance ...

Livtencity is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates. The Food and Drug Administration (FDA) has approved Livtencity ...

Credit: Getty Images. The NDA submission is supported by data from the multicenter, randomized, open-label, active-controlled phase 3 TAK-620-303 (SOLSTICE) trial. The Food and Drug Administration ...

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted priority review to maribavir for the treatment of patients with transplant-associated ...

Although valganciclovir is an effective CMV prophylactic agent after kidney transplantation, it is associated with significant side effects. Valacyclovir (valA) is effective and more tolerable than ...

Takeda has shared results from a successful phase 3 clinical trial of maribavir in transplant recipients with refractory cytomegalovirus (CMV) infection. The trial suggests maribavir is better at ...

A kidney transplant recipient in their mid-30s developed new-onset floaters in both eyes, according to a case report in JAMA Ophthalmology. The patient had received a kidney from a deceased donor.

- LIVTENCITY Is the First and Only Inhibitor of CMV-specific UL97 Protein Kinase Approved in China for the Treatment of Adults With Post-transplant CMV Infection/Disease Refractory* to Conventional ...